Forge Biologics Announces Closing of $120 Million Series B Financing
29.4.2021 15:00:00 EEST | Business Wire | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund will join the Company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005365/en/
“We are very pleased to be working with RA Capital and a strong syndicate of top-tier life sciences investors who share our vision as we now advance our growth as a global gene therapy manufacturing and development company,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “We have built Forge into a focused gene therapy development engine with a firm commitment to helping our clients provide potentially life-saving gene therapies to patients. We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently delivering high quality product.”
Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. Forge brings a patients-first approach to accelerate the development of transformative medicines for those who need them most and is addressing the growing demand for gene therapy manufacturing capacity. Through its currently-operational 175,000 square foot cGMP facility in Columbus, Ohio, dedicated to AAV viral vector manufacturing, Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
“The success of complex biologics like AAV is exhausting existing manufacturing capacity around the industry. This financing will help to address this industry-wide capacity shortage by properly capitalizing an emerging gene therapy-focused CDMO capable of producing high quality cGMP product for its clients,” said Matthew Hammond, Ph.D., principal at RA Capital Management. “We are confident that Forge’s experienced team will become the trusted partner of innovative therapeutics companies, working collaboratively with clients to successfully deliver AAV manufacturing solutions.”
Through its subsidiaries, Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Chardan Capital Markets acted as exclusive placement agent for the offering, with Ice Miller acting as legal advisor.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005365/en/
Contact information
Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com
Business Development:
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com
Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Forge Biologics Inc.
Investors@forgebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Steady concentration PD with the Carry Life UF system increased ultrafiltration nearly threefold and sodium removal nearly tenfold vs 2.5% dextrose CAPD, while improving glucose efficiency and supporting enhanced fluid management in PD patients4.6.2026 17:45:00 EEST | Press release
Triomed AB today announced positive results from a prospective, multicenter, randomized, crossover study evaluating steady concentration peritoneal dialysis using the Carry Life UF system in adult patients undergoing CAPD. The study demonstrated significant improvements in ultrafiltration, peritoneal sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume in relation to glucose absorption) compared with standard 2.5% dextrose CAPD in the home setting over four weeks. The study results were presented as a Focussed Oral presentation based on a late-breaking clinical trial abstract at the European Renal Association (ERA) Congress in Glasgow, United Kingdom, and simultaneously published in the Journal of the American Society of Nephrology (JASN). In this study, participants received their standard CAPD treatment during the control arm, whereas in the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced by a Carry Life UF treatment three days per week, and
The Empire State Building’s Tastes of New York Experience to Feature Eataly4.6.2026 17:44:00 EEST | Press release
The Empire State Building (ESB), the “World’s Most Famous Building,” today announced that it will feature Eataly as its latest Tastes of New York Experience, a year-round offering of pop-ups which feature unique New York City bites. From June 4 through Aug. 31, Eataly will bring its New York City spin on “la dolce vita” to the Empire State Building’s iconic Observation Deck with a curated selection of its most beloved desserts and beverages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604332533/en/ Gelato, cannoli, and tiramisù available on the 86th Floor Observation Deck from June 4 through Aug. 31 “We are excited to present Eataly’s true ‘estate Italiana’ as part of our year-round featured Tastes of New York to our visitors,” said Dan Rogoski, observatory general manager. “The Empire State Building can be seen and photographed all around New York City, but only a visit to our Observatory Deck gives you the most authe
JCÖNTENTS “Zip to your destination, even with a language barrier.”4.6.2026 17:00:00 EEST | Press release
JCÖNTENTS releases free GOPin smartphone app on June 1! JCÖNTENTS Co., Ltd. (Kyoto Prefecture; Representative: Takamasa Yoshimitsu) released the free GOPin app for smartphones on June 1! GOPin is a completely new, multilingual navigation app that connects tourists visiting Japan with local taxi drivers through QR codes. All users have to do is select where they want to go on the map and show the QR code. The taxi driver will scan that to instantly display an accurate route in Google Maps. No more worries about entering addresses or pronunciation issues. GOPin doesn’t require any user registration and is free to use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601449250/en/ GOPin! For Visitors to Japan Say goodbye to the language barrier— just show your smartphone to the taxi driver! Multilingual map function: *Available in English, Japanese, Chinese (traditional, simplified), and Korean. Easily find your destination in
Impartner Recognized as a Leader in G2 Summer 2026 Enterprise Grid® for Partner Relationship Management4.6.2026 16:00:00 EEST | Press release
Impartner, the world’s leading partner revenue orchestration platform, today announced it has been named a Leader in the G2 Summer 2026 Enterprise Grid® Report for Partner Relationship Management (PRM). The recognition underscores Impartner’s strong customer validation and continued momentum among enterprise organizations managing large-scale partner ecosystems and indirect sales channels. In the Summer 2026 report, Impartner earned Leader status based on strong customer satisfaction and adoption across organizations operating at scale. G2’s findings show a 4.5 out of 5-star rating from more than 500 verified reviews, with 91% of users indicating they would recommend the platform. Customers gave high marks for key capabilities, including Role-Based Permissions, Deal Management, and Content Repository, with Ease of Doing Business With as the highest-rated category, reflecting a strong user experience driven by a dedicated customer success team, responsive support, and a commitment to in
Tsuno Rice Fine Chemicals: Comparative Absorption Study of Rice Bran-Derived “Rice Magnesium” Reveals New Insights into Its Gradual, Sustained Absorption Profile4.6.2026 16:00:00 EEST | Press release
Tsuno Rice Fine Chemicals Co., Ltd. announced findings from an in-house human study showing that its proprietary rice bran-derived ingredient, “Rice Magnesium,” delivers gradual, sustained magnesium absorption compared with other magnesium sources. The results suggest potential benefits for sleep maintenance, muscle fatigue management during prolonged exercise, and gentler digestive tolerance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604576648/en/ Tsuno Rice Fine Chemicals: Differences in Absorption Among Magnesium Supplements Product Name: Rice Magnesium Most magnesium ingredients currently available on the market are mineral-derived. In contrast, Rice Magnesium is a rare plant-based magnesium ingredient sourced from rice bran, developed through Tsuno’s long-standing rice bran research. Composition: Magnesium phosphate Source Material: Japanese rice bran Study Background Magnesium is an essential mineral involved i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom